The effect of magnesium and zinc and probiotic co-supplementation in patients with coronary heart disease and type 2 diabetes mellitus

Study of the effect of magnesium and zinc and probiotic co-supplementation on metabolic profiles in patients with coronary heart disease and type 2 diabetes mellitus

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT20130211012438N35

Enrollment

Registered

2023-06-06

Start date

2019-01-05

Completion date

Unknown

Last updated

2023-06-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

coronary heart disease and type 2 diabetes mellitus. Chronic ischemic heart disease, unspecified

Interventions

Intervention 1: Intervention group: A capsule containing 150 mg zinc sulfate and 250 mg magnesium oxide and a probiotic capsule (containing Lactobacillus acidophilus 109 × 1.8, Bifidobacterium bifid

Eligibility

Sex/Gender

All

Age

40 Years to 95 Years

Inclusion criteria

Inclusion criteria: Coronary heart disease patients diagnosed with angiography; Patients with diabetes according to American Diabetes Association criteria; age 40 to 95 years; No smoking

Exclusion criteria

Exclusion criteria: Thyroid disease; Infection; Consumption of any type of supplement (vitamin, salts, etc.) in the last 3 months; Acute myocardial infarction in the last 3 months; Cardiac surgery in the last 3 months; Significant kidney failure; Significant liver failure; Unwillingness to cooperate; Antibiotic use during study

Design outcomes

Primary

Measure	Time frame
Insulin resistance. Timepoint: Baseline and End-of-trial. Method of measurement: Calculate with HOMA formula.	—

Secondary

Measure	Time frame
Fasting plasma glucose. Timepoint: Baseline and end of the trial. Method of measurement: Enzymatic.;Insulin. Timepoint: Baseline and end of the trial. Method of measurement: Elisa.;Insulin sensitivity. Timepoint: Baseline and end of the trial. Method of measurement: Calculate with QUICKI formula.;HbA1c. Timepoint: Baseline and end of the trial. Method of measurement: Laboratory clinical kit.;Nitric oxide (NO). Timepoint: Baseline and end of the trial. Method of measurement: Spectrophotometry.;High sensitivity C-reactive protein (hs-CRP). Timepoint: Baseline and end of the trial. Method of measurement: Elisa.;Total Antioxidant Capacity (TAC). Timepoint: Baseline and end of the trial. Method of measurement: Spectrophotometry.;Total glutathione. Timepoint: Baseline and end of the trial. Method of measurement: Spectrophotometry.;Malondialdehyde (MDA). Timepoint: Total glutathione. Method of measurement: Spectrophotometry.;Serum Total cholestrol. Timepoint: Baseline and end of the trial. Method of measurement: Laboratory clinical kit.;Serum LDL-C. Timepoint: Baseline and end of the trial. Method of measurement: Laboratory clinical kit.;HDL-C ???. Timepoint: Baseline and end of the trial. Method of measurement: Laboratory clinical kit.;Serum Triglyceride. Timepoint: Baseline and end of the trial. Method of measurement: Laboratory clinical kit.	—

Measure

Time frame

Fasting plasma glucose. Timepoint: Baseline and end of the trial. Method of measurement: Enzymatic.;Insulin. Timepoint: Baseline and end of the trial. Method of measurement: Elisa.;Insulin sensitivity. Timepoint: Baseline and end of the trial. Method of measurement: Calculate with QUICKI formula.;HbA1c. Timepoint: Baseline and end of the trial. Method of measurement: Laboratory clinical kit.;Nitric oxide (NO). Timepoint: Baseline and end of the trial. Method of measurement: Spectrophotometry.;High sensitivity C-reactive protein (hs-CRP). Timepoint: Baseline and end of the trial. Method of measurement: Elisa.;Total Antioxidant Capacity (TAC). Timepoint: Baseline and end of the trial. Method of measurement: Spectrophotometry.;Total glutathione. Timepoint: Baseline and end of the trial. Method of measurement: Spectrophotometry.;Malondialdehyde (MDA). Timepoint: Total glutathione. Method of measurement: Spectrophotometry.;Serum Total cholestrol. Timepoint: Baseline and end of the trial. Method of measurement: Laboratory clinical kit.;Serum LDL-C. Timepoint: Baseline and end of the trial. Method of measurement: Laboratory clinical kit.;HDL-C ???. Timepoint: Baseline and end of the trial. Method of measurement: Laboratory clinical kit.;Serum Triglyceride. Timepoint: Baseline and end of the trial. Method of measurement: Laboratory clinical kit.

—

Countries

Iran (Islamic Republic of)

Contacts

Public Contactzahra Hamedifard

Kashan University of Medical Sciences

z.hamedifard.sb@gmail.com+98 31 5554 0021

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026